ReviewVascular health and risk management2020
Barriers to Early Diagnosis and Treatment of Familial Hypercholesterolemia: Current Perspectives on Improving Patient Care.
Review in Vascular health and risk management, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 48 citations in OpenAlex.
- Trial
- Familial Hypercholesterolemia in Latin America: Unmet Needs, Barriers, and Challenges.Journal of lipid and atherosclerosis · 2026Review
- Co-Design of Strategies to Support the Implementation of a Paediatric Risk-Reduction Pathway for Familial Hypercholesterolaemia.Journal of paediatrics and child health · 2026Article
- Familial Hypercholesterolemia in Women: Diagnosis, Treatment, and Cardiovascular Outcomes Across the Lifespan.Current atherosclerosis reports · 2026Review
- Novel Therapies, Residual Risk, Familial Hypercholesterolemia, and Digital Tools: Multispecialty Insights from a Dyslipidemia Management Survey.Journal of clinical medicine · 2026Article
- Risk prediction and prevention in patients with advanced subclinical atherosclerosis.BMC cardiovascular disorders · 2026Review
- Healthcare activities before familial hypercholesterolemia diagnosis: a nationwide register-based study in Denmark.BMC primary care · 2026Article
- Prevalence of Familial Hypercholesterolemia and Its Association with Cardiovascular Risk in a Cross-Sectional Adult Population.Journal of clinical medicine · 2025Article
- Implementing Precision Medicine for Dilated Cardiomyopathy: Insights From the DCM Consortium.Circulation. Genomic and precision medicine · 2025Article
- Enhancing Familial Hypercholesterolemia Detection in South Korea: A Targeted Screening Approach Integrating National Program and Genetic Cascade Screening.Korean circulation journal · 2024Article
- Review
- The Power of the Pedigree: Cascade Screening in Familial Hypercholesterolemia.JACC. Advances · 2024Article
- A machine-learning algorithm using claims data to identify patients with homozygous familial hypercholesterolemia.Scientific reports · 2024Article
- Comparison of Two Strategies for Hypercholesterolemia Detection through Point-of-Care Testing.Diagnostics (Basel, Switzerland) · 2024Article
- Diagnosis of Familial Hypercholesterolemia in Children and Young Adults.International journal of molecular sciences · 2023Article
- Prevalence and factors associated with possible cases of familial hypercholesterolemia in Brazilian adults: a cross-sectional study.Scientific reports · 2023Article
- Article
- How Can Implementation Science Improve the Care of Familial Hypercholesterolaemia?Current atherosclerosis reports · 2023Review
- Real-world utilization of guideline-directed genetic testing in inherited cardiovascular diseases.Frontiers in cardiovascular medicine · 2023Article
- Patient experiences align with the familial hypercholesterolemia global call to action.American journal of preventive cardiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Familial hypercholesterolemia (FH) is a frequent disorder associated with premature atherosclerotic cardiovascular disease. Different clinical diagnosis criteria are available, and cost of genetic testing has been reduced in the last years; however, most cases are not diagnosed worldwide. Patients with FH are at high cardiovascular risk and the risk can be reduced with lifelong lifestyle and pharmacological treatment. Statins and ezetimibe are available as generic drugs in most countries reducing the cost of treatment. However, the use of high-intensity statins combined with ezetimibe and PCSK9 inhibitors, if necessary, is low for different reasons that contribute to a high number of patients not reaching LDL-C targets according to guidelines. On the other hand, cardiovascular risk varies greatly in families with FH; therefore, risk stratification strategies including cardiovascular imaging is another element to consider for improving care and management of FH. There are numerous barriers depending on the awareness, knowledge, perception of risk, management and care of patients living with FH that impact in the diagnosis and treatment of the disorder. In this contemporary review, we analyze different barriers in the diagnosis and care of patients to improve patients' care and prevention of atherosclerotic cardiovascular disease and describe recent advances and strategies to improve the gaps in the care of FH, including global collaboration and advocacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.